At a compound annual growth rate (CAGR) of 4.5% over the projected years, the global vaginal antifungals market is predicted to reach a value of US$ 1.09 billion in 2022. A recent analysis by Future Market Insights predicts that Polygenes will hold the top spot in the global market in 2022 with a share of roughly 49.0%.

During the projection period, it is anticipated that the global market for Vaginal Antifungals will expand significantly. This can be attributed to the expansion of novel antifungal drug research and the global increase in healthcare spending. Additionally, the market is being driven by the increased incidence of bacterial vaginosis. In women of reproductive age, it is the most frequent source of vaginal discharge that results in fungus infections.

Rising trichomoniasis and candida occurrences are also assisting market growth for Vaginal Antifungals. The primary causes of candida growth that leads to vaginal yeast infection include a weakened immune system and the use of oral contraceptives or hormone therapy that increases estrogen levels.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17096

In addition, businesses are concentrating on winning clearance for innovative items that could fill unmet demands and strengthen their market position. Additionally, the growing need for better therapeutic options is spurring advancements in RD, fresh approvals, and drug launches, opening up a lucrative window for business expansion.

Key Takeaways:

• Polyenes are the leading segment as product, and hold around 49.0% market value share in 2022, owing to less adverse effects and low product cost.
• Topical segment is set to lead in the of route of administration segment of Vaginal Antifungals market with a projected market value share of around 73.1% in 2022, owing to the high preference by doctors and effective cure for the disease.
• Bacterial Vaginosis is leading the indication segment with the significant market share of 44.9% owed to increased prevalence compared to other indications.
• By distribution channel, Gynaecology clinics held a share of around 41.4% in 2022, as patient pool largely comprises of female population who prefer to get consultation and treatment at Gynecology centers.
• North America dominated the global market with significant contribution from U.S. region. US held a value share of around 27.0% in 2022 globally, due to rising prevalence of trichomoniasis in the region.

“Rising prevalence of severe vaginal infectious disorders, increasing rate of testing and launch of Vaginal Antifungals by players will boost the global market for Vaginal Antifungals,” says an analyst at Future Market Insights.

Market Competition:

The market participants are concentrating on creating and introducing enhanced treatment drugs in order to increase the accuracy and efficiency of the operations and reduce adverse effect problems.

• Brexafemme, a high-class antifungal for the treatment of vulvovaginal candidiasis (VCC), will be commercialised and further developed by GSK plc and SCYNEXIS Inc. in 2023 under an exclusive licencing agreement. These drugs have also been approved by the FDA.

Key Players:

• Pfizer Inc.
• Bausch Health Companies Inc
• ANI Pharmaceuticals, Inc.
• Hikma Pharmaceuticals Plc
• Lupin Limited
• Mycovia Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• GSK plc.
• Others

Key Segments:

By Product:

• Polyenes
• Azoles
• Allylamines
• Echinocandins
• Others

By Route of Administration:

• Oral
• Topical

By Indication:

• Bacterial Vaginosis
• Candidiasis
• Trichomoniasis
• Others

Distribution Channel:

• Hospital Pharmacies
• Supermarkets/hypermarkets
• Online Pharmacies
• Gynecology Clinics
• Others